S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones

MacroGenics Stock Price, News & Analysis (NASDAQ:MGNX)

$8.71
-0.22 (-2.46%)
(As of 12/8/2023 ET)
Compare
Today's Range
$8.66
$9.10
50-Day Range
$4.48
$8.93
52-Week Range
$4.29
$9.10
Volume
379,432 shs
Average Volume
564,302 shs
Market Capitalization
$540.28 million
P/E Ratio
10.89
Dividend Yield
N/A
Price Target
$11.83

MacroGenics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
35.9% Upside
$11.83 Price Target
Short Interest
Bearish
11.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.15mentions of MacroGenics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$669,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.73) to ($1.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

151st out of 932 stocks

Pharmaceutical Preparations Industry

52nd out of 431 stocks


MGNX stock logo

About MacroGenics Stock (NASDAQ:MGNX)

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX Stock Price History

MGNX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Reviewing MacroGenics (NASDAQ:MGNX) & Pfizer (NYSE:PFE)
Guggenheim Upgrades Macrogenics (MGNX)
MacroGenics (MGNX) Q3 2023 Earnings Call Transcript
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
MacroGenics files for $300M mixed shelf
MacroGenics: Q3 Earnings Snapshot
What Wall Street expects from Macrogenics's earnings
A Preview Of Macrogenics's Earnings
BMO Capital Remains a Buy on MacroGenics (MGNX)
JMP Securities Sticks to Its Buy Rating for MacroGenics (MGNX)
MGNX - MacroGenics, Inc.
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGNX
Employees
357
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$11.83
High Stock Price Target
$17.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+35.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-119,760,000.00
Pretax Margin
41.13%

Debt

Sales & Book Value

Annual Sales
$151.94 million
Book Value
$2.31 per share

Miscellaneous

Free Float
55,826,000
Market Cap
$540.28 million
Optionable
Optionable
Beta
2.08

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Scott Koenig M.D. (Age 71)
    Ph.D., President, CEO & Director
    Comp: $1.06M
  • Mr. James KarrelsMr. James Karrels (Age 56)
    Senior VP, CFO & Corporate Secretary
    Comp: $626.83k
  • Mr. Eric Blasius Risser (Age 50)
    Chief Operating Officer
    Comp: $651.36k
  • Dr. Thomas M. Spitznagel Ph.D. (Age 56)
    Senior Vice President of Technical Operations
    Comp: $550.97k
  • Dr. Ezio Bonvini (Age 69)
    Senior VP of Research & Chief Scientific Officer
    Comp: $612.21k
  • Mr. Jeffrey Stuart Peters (Age 52)
    Senior VP, General Counsel & Corporate Compliance Officer
  • Dr. Stephen L. Eck M.D. (Age 68)
    Ph.D., Senior VP of Clinical Development & Chief Medical Officer
    Comp: $577.62k
  • Ms. Lynn Cilinski (Age 65)
    VP, Controller & Treasurer














MGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price target for 2024?

5 Wall Street research analysts have issued 1-year price objectives for MacroGenics' stock. Their MGNX share price targets range from $8.00 to $17.00. On average, they predict the company's share price to reach $11.83 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2023?

MacroGenics' stock was trading at $6.71 at the beginning of the year. Since then, MGNX shares have increased by 29.8% and is now trading at $8.71.
View the best growth stocks for 2023 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.49. The biopharmaceutical company had revenue of $10.40 million for the quarter, compared to analysts' expectations of $54.80 million. MacroGenics had a net margin of 41.13% and a negative trailing twelve-month return on equity of 51.83%.

What ETF holds MacroGenics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 221,160 shares of MGNX stock, representing 1.03% of its portfolio.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (7.60%), Acadian Asset Management LLC (2.21%), Silverarc Capital Management LLC (2.04%), Rock Springs Capital Management LP (1.90%), Federated Hermes Inc. (1.50%) and Charles Schwab Investment Management Inc. (1.33%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MGNX) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -